Cantor Fitzgerald Issues Positive Outlook for BCYC Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Stock analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for shares of Bicycle Therapeutics in a note issued to investors on Wednesday, February 26th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings of ($3.49) per share for the year, up from their prior forecast of ($4.24). The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.10. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.47 million. During the same period in the previous year, the firm earned ($1.16) EPS. The business’s quarterly revenue was down 30.2% on a year-over-year basis.

A number of other research analysts have also recently commented on BCYC. HC Wainwright reissued a “buy” rating and issued a $33.00 price target on shares of Bicycle Therapeutics in a report on Wednesday. JMP Securities lowered their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Stephens reissued an “equal weight” rating and issued a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. B. Riley lowered their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $30.00 price target on shares of Bicycle Therapeutics in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.14.

Bicycle Therapeutics Trading Down 0.5 %

NASDAQ BCYC opened at $10.97 on Friday. The stock’s 50 day moving average is $13.19 and its 200 day moving average is $19.32. Bicycle Therapeutics has a 12 month low of $10.81 and a 12 month high of $28.67. The stock has a market cap of $757.43 million, a PE ratio of -3.33 and a beta of 0.93.

Hedge Funds Weigh In On Bicycle Therapeutics

Several large investors have recently modified their holdings of the stock. Baker BROS. Advisors LP increased its position in shares of Bicycle Therapeutics by 15.8% during the 4th quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company’s stock valued at $152,395,000 after purchasing an additional 1,485,397 shares during the last quarter. Point72 Asset Management L.P. increased its position in shares of Bicycle Therapeutics by 406.2% during the 4th quarter. Point72 Asset Management L.P. now owns 4,554,900 shares of the company’s stock valued at $63,769,000 after purchasing an additional 3,655,101 shares during the last quarter. Fcpm Iii Services B.V. increased its position in shares of Bicycle Therapeutics by 47.5% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company’s stock valued at $48,333,000 after purchasing an additional 1,112,369 shares during the last quarter. Westfield Capital Management Co. LP increased its position in shares of Bicycle Therapeutics by 21.5% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company’s stock valued at $41,887,000 after purchasing an additional 327,089 shares during the last quarter. Finally, Candriam S.C.A. boosted its holdings in Bicycle Therapeutics by 3.5% during the 4th quarter. Candriam S.C.A. now owns 1,087,876 shares of the company’s stock valued at $15,230,000 after acquiring an additional 37,278 shares during the period. Institutional investors own 86.15% of the company’s stock.

Insiders Place Their Bets

In related news, Director Bros. Advisors Lp Baker bought 985,397 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were purchased at an average price of $13.76 per share, with a total value of $13,559,062.72. Following the transaction, the director now owns 9,537,643 shares in the company, valued at $131,237,967.68. This trade represents a 11.52 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Travis Alvin Thompson sold 2,686 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $15.00, for a total value of $40,290.00. Following the transaction, the chief accounting officer now directly owns 32,146 shares in the company, valued at approximately $482,190. This represents a 7.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,677 shares of company stock valued at $392,413 in the last quarter. 8.50% of the stock is currently owned by insiders.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.